Tislelizumab in patients with unresectable HCC demonstrates durable responses

Impact of timing of perioperative chemotherapy on OS in patients with CRC liver metastases

Impact of gender and HPV status on anal squamous cell carcinoma survival

1L NALIRIFOX in advanced or metastatic PDAC

Monitoring MRD by ctDNA in resectable CRC

Treating CRC with regorafenib in Latin America

CRC highlights from ESMO WCGIC 2021

Tiragolumab and atezolizumab in metastatic esophageal cancer

KEYNOTE-811: trastuzumab + chemotherapy with or without pembrolizumab for HER2+ G/GEJ cancer

MATTERHORN: neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable G/GEJ

Treatment of CRC in adjuvant setting

BEACON CRC: first-line bevacizumab in colorectal cancer treatment

Averectal: neoadjuvant short-course RT followed by chemo + avelumab in rectal adenocarcinoma

Updates to look out for at ESMO WCGIC 2021

Early colon and rectal cancer at ESMO WCGIC 2021

VALENTINO: VAF as prognostic marker in mCRC